BazEkon - The Main Library of the Cracow University of Economics

BazEkon home page

Main menu

Author
Pohulak-Żołędowska Elżbieta (Wrocław University of Economics, Poland)
Title
Common Resources in Open Innovation Model as the Competition Driving Agents
Source
Ekonomia i Prawo, 2014, t. 13, nr 4, s. 559-572, rys., bibliogr. 22 poz.
Economics and Law
Keyword
Otwarte innowacje, Innowacyjność, Współpraca, Zasoby wiedzy, Przemysł farmaceutyczny, Sfera B+R w przedsiębiorstwie
Open innovation, Innovative character, Cooperation, Knowledge resources, Pharmaceutical industry, R&D in the enterprise
Note
summ.
Abstract
The hereby article is addressed to the problem of innovation in new, Academia rooted industries. The traditional models of innovation seem to fail, whilst R&D activity of companies is more and more risky, and expensive. An example of pharmaceutical industry is given here. Pharmaceutical (and especially biopharmaceutical) industry widely adopts the open innovation model in order to increase innovation. Opening of the innovation process is a novelty in these industries, as the secrecy and inward research activity have been the key features of Big Pharma's success. Creation of common knowledge platform that enables the communication between researches makes the innovation environment more collaborative but also competitive. Common, open information platform lowers the cost of innovation and also, thanks to the researchers' collaborative behavior, helps to face the big challenges of contemporary societies. The collaboration on the research phase does not exclude the competition. Those are companies that compete, as the prize is profit. Commonly built resources only facilitate the competition process. (original abstract)
Full text
Show
Bibliography
Show
  1. Allarakhia M., Novartis Institutes for Biomedical Research, @CanBiotech Inc., 2011.
  2. Austin C.P, Brady L.S., Insel T.R., Collins F.S., NIH Molecular Libraries Initiative, "Science", Vol. 306, No. 5699/2004, http://dx.doi.org/10.1126/science.1105511.
  3. Benkler Y., Nissenbaum H., Commons-based Peer Production and Virtue, "The Journal of Political Philosophy", Vol. 14, No. 4/2006, http://dx.doi.org/10.1111/j.1467-9760.2006.00235.x.
  4. Chesbrough H., Open Innovation. The New Imperative for Creating and Profiting from Technology, Harvard Business School Press, Boston 2003.
  5. Chesbrough H., Open Innovation: A New Paradigm for Understanding Industrial Innovation, [in:] Chesbrough H., Vanhaverbeke W., West J. (ed.), Open Innovation Researching a New Paradigm, Oxford University Press, Oxford 2006.
  6. Chesbrough H., Vanhaverbeke W., West J., Open Innovation Researching a New Paradigm, Oxford University Press, Oxford 2006.
  7. Czetwertyński S., Produkcja partnerska w internecie jako przykład globalnej dezintegracji procesu produkcji, "Ekonomia i Prawo"., Vol. XI, No. 4/2012, http://dx.doi.org/10.12775/eip.2012.032.
  8. Gavura S., What does a new drug cost? Part II: The productivity problem, http://www.sciencebasedmedicine.org/what-does-a-new-drug-cost-part-ii-the-productivity-problem/ (20.05.2013).
  9. Herper M., How Much Does Pharmaceutical Innovation Cost? A Look At 100 Companies, http://www.forbes.com/sites/matthewherper/2013/08/11/the-cost-of-inventing-a-new-drug-98-companies-ranked/ (20.05.2013).
  10. Herzog Ph., Open and Closed Innovation. Different Cultures for Different Strategies, Gabler Verlag, Heidelberg 2011.
  11. Kline S.J., Rosenberg N., An overview of innovation, [in:] R. Landau, N. Rosenberg (eds), The Positive Sum Strategy: Harnessing Technology for Economic Growth, Washington, National Academy Press, Washington 1986.
  12. Munoz B., Lessons From 60 Years of Pharmaceutical Innovation, "Nature Review Drug Discovery", Vol. 8, No. 12/2009, http://dx.doi.org/10.1038/nrd2961.
  13. Muralitharan M. et al., Open Innovation: Next Frontier In Global Biopharma Industry, "Asia-Pacific Biotech News", Vol. 14, No. 4/2010.
  14. OECD, Technology and Industry Scoreboard 2011, http://www.oecd-ilibrary.org/science-and-technology/oecd-science-technology-and-industry-scoreboard-2011_sti_scoreboard-2011-en (20.05.2013).
  15. Research and Development in the Pharmaceutical Industry, The Congress of the United States - Congressional Budget Office, No. 2589/2006, http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/76xx/doc7615/10-02-drugr-d.pdf (20.05.2013).
  16. Roy A. et al., Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making, Vol. 11, No. 7/2010, http://dx.doi.org/10.2174/138920110792927757.
  17. Roy A., McDonald R.P., Chaguturu R., Recent Trends in Collaborative, Open Source Drug Discovery, "The Open Conference Proceedings Journal", Vol. 2, No. 1/2011, http://dx.doi.org/10.2174/2210289201102010130.
  18. Schumpeter J., Teorie rozwoju gospodarczego, PWN, Warszawa 1960.
  19. Tidd J., A Review of Innovation Models, Tanaka Business School, Imperial College, London 2006, http://www.emotools.com/media/upload/files/innovation_models.pdf (20.05.2013).
  20. Tidd J., Bessant, J., Pavitt, K., Managing Innovation: Integrating technological, market and organizational change, Third edition, Wiley, 2005.
  21. Waguespack D.M., Fleming L, Scanning the Commons? Evidence on the Benefits to Startups Participating in Open Standards Development, "Management Science", Vol. 55, No. 2/2009, http://dx.doi.org/10.1287/mnsc.1080.0944.
  22. Waldron R.F., Open Innovation in Pharma - Defining Dialogue, http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=788391&pageID=1&sk=&date= (20.05.2013).
Cited by
Show
ISSN
1898-2255
Language
eng
URI / DOI
http://dx.doi.org/10.12775/EiP.2014.040
Share on Facebook Share on Twitter Share on Google+ Share on Pinterest Share on LinkedIn Wyślij znajomemu